Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis.
Adolescent
Adult
Aged
Aged, 80 and over
Child
Child, Preschool
Chromosome Aberrations
Core Binding Factor Alpha 2 Subunit
/ genetics
Female
Gastrointestinal Diseases
/ physiopathology
Hematologic Neoplasms
/ complications
Hepatomegaly
/ physiopathology
Humans
Infant
Infant, Newborn
Leukemia, Mast-Cell
/ physiopathology
Leukemia, Myeloid, Acute
/ complications
Male
Mastocytosis, Systemic
/ complications
Middle Aged
Myelodysplastic Syndromes
/ complications
Prognosis
Progression-Free Survival
Proto-Oncogene Proteins c-kit
/ genetics
Repressor Proteins
/ genetics
Serine-Arginine Splicing Factors
/ genetics
Sex Factors
Skin Diseases
/ physiopathology
Splenomegaly
/ physiopathology
Survival Rate
Young Adult
Mastocytosis
cytogenetics
molecular mutations
sex difference
survival
Journal
Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
08
2020
accepted:
23
09
2020
entrez:
4
1
2021
pubmed:
5
1
2021
medline:
6
8
2021
Statut:
epublish
Résumé
In systemic mastocytosis (SM), the clinical features and survival vary greatly. Patient-related factors determining the outcome in SM are largely unknown.
Identifiants
pubmed: 33391475
doi: 10.7150/thno.51872
pii: thnov11p0292
pmc: PMC7681091
doi:
Substances chimiques
ASXL1 protein, human
0
Core Binding Factor Alpha 2 Subunit
0
RUNX1 protein, human
0
Repressor Proteins
0
SRSF2 protein, human
147153-65-9
Serine-Arginine Splicing Factors
170974-22-8
KIT protein, human
EC 2.7.10.1
Proto-Oncogene Proteins c-kit
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
292-303Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: Hanneke C. Kluin-Nelemans: institutional financial support from Novartis; honoraria from Novartis for participating in e-learning program. Andreas Reiter: Novartis Pharma - research support, advisory board, honoraria, travel reimbursement, Blueprint Medicines - advisory board, honoraria, travel reimbursement, Deciphera - advisory board, travel reimbursement. Bjorn van Anrooij: financial support from Novartis for research and advisory boards. Jason Gotlib: Funding to support conduct of clinical trial: Blueprint Medicines, Deciphera; advisory board/honoraria: Blueprint Medicines, Deciphera, Allakos. Karin Hartmann: advisory board/honoraria: Allergopharma, ALK-Abelló, Blueprint, Deciphera, Menarini, Novartis and Takeda; research grant: Euroimmun. Hanneke Oude Elberink: honoraria from ALK-Abelló, Chiesi, MEDA Pharma, Novartis, and Blueprint. Magdalena Lange: honoraria from Novartis for lectures. Chiara Elena: advisory board Novartis, Pfizer. David Fuchs, Julien Rossignol: advisory board Novartis. Khalid Shoumariyeh: travel support from Abbvie and consultancy fees from Novartis. Nikolas von Bubnoff: institutional financial support from Novartis. Massimo Triggiani: advisory board BluePrint Medicines, Deciphera, Novartis. Akif SelimYavuz: honoraria from Novartis. Jens Panse: funding to support conduct of clinical trial: Blueprint Medicines, Deciphera; advisory board/honoraria: Blueprint Medicines, Novartis. Vito Sabato: advisory board/honoraria: Blueprint Medicines, Novartis. Madlen Jentzsch: honoraria from Novartis. Olivier Hermine: Research funding support from AB science and Novartis. Advisory board of AB science. Wolfgang R. Sperr: honoraria from Novartis, Pfizer, AbbVie, Daiichi Sankyo, Amgen, Thermo Fisher, Deciphera, Incyte, Celgene and Jazz. Michel Arock: advisory board/honoraria Blueprint Medicines, Deciphera. All other authors: none.
Références
Blood Adv. 2018 Nov 13;2(21):2964-2972
pubmed: 30413432
Br J Haematol. 2014 Aug;166(4):521-8
pubmed: 24761987
J Allergy Clin Immunol. 2016 Jan;137(1):35-45
pubmed: 26476479
Cell Stem Cell. 2018 Feb 1;22(2):157-170
pubmed: 29395053
Allergy. 2012 Mar;67(3):431-8
pubmed: 22229787
Leukemia. 2016 Jan;30(1):136-43
pubmed: 26464169
Blood. 2009 Oct 29;114(18):3769-72
pubmed: 19713463
Curr Opin Hematol. 2010 Mar;17(2):125-32
pubmed: 20075725
Br J Haematol. 2018 Jan;180(1):11-23
pubmed: 29048112
Blood. 2020 Apr 16;135(16):1365-1376
pubmed: 32106312
Blood. 2009 Jun 4;113(23):5727-36
pubmed: 19363219
Haematologica. 2017 Jun;102(6):1035-1043
pubmed: 28255023
Lancet Haematol. 2019 Dec;6(12):e638-e649
pubmed: 31676322
Am J Hematol. 2016 Sep;91(9):888-93
pubmed: 27214377
Leukemia. 2016 Dec;30(12):2342-2350
pubmed: 27416984
Leukemia. 2015 Jun;29(6):1223-32
pubmed: 25650093
J Allergy Clin Immunol Pract. 2019 Jan;7(1):81-87
pubmed: 30416055
Leuk Res. 2001 Jul;25(7):603-25
pubmed: 11377686
N Engl J Med. 2015 Jul 9;373(2):163-72
pubmed: 26154789
J Allergy Clin Immunol Pract. 2017 Sep - Oct;5(5):1248-1255
pubmed: 28351784
J Clin Oncol. 2019 Nov 1;37(31):2846-2856
pubmed: 31509472
Blood. 2019 Aug 1;134(5):456-468
pubmed: 31151985
J Clin Oncol. 2005 Mar 20;23(9):1969-78
pubmed: 15632409
Clin Exp Allergy. 2007 Oct;37(10):1547-55
pubmed: 17883734
Am J Hematol. 2018 Dec;93(12):1461-1466
pubmed: 30152525
Pathol Res Pract. 1985 Mar;179(4-5):439-61
pubmed: 2582403
Br J Dermatol. 2015 Mar;172(3):642-51
pubmed: 25662299
Mayo Clin Proc. 2018 Aug;93(8):1122-1130
pubmed: 30078412
Theranostics. 2020 Aug 29;10(23):10743-10768
pubmed: 32929378
N Engl J Med. 2016 Jun 30;374(26):2530-41
pubmed: 27355533
Cancer Res. 2017 Mar 15;77(6):1261-1270
pubmed: 28254862
Genes Chromosomes Cancer. 2018 May;57(5):252-259
pubmed: 29341334
N Engl J Med. 2014 Dec 25;371(26):2488-98
pubmed: 25426837